Osteosarcoma, the most common bone cancer, usually affects children or adolescents during their pubertal growth spurt. Prognosis is poor for patients with advanced osteosarcoma, with low overall survival rates and limited therapeutic options. To identify better treatment options for osteosarcoma, the authors led by A/Prof Victor Lee, investigated the effect of ETC-159, a promising new drug which targets Wnt, a protein known to play an important role in cancer development and progression.  Treatment with ETC-159 resulted in reduced tumour-associated blood vessel development and increased tumour cell death in preclinical osteosarcoma models. By describing the treatment effects of ETC-159, this study identifies potential avenues for the combination of ETC-159 with other therapies to enhance treatment efficacy for osteosarcoma.

Read more: https://www.mdpi.com/1422-0067/24/5/4759#:~:text=Treatment%20with%20ETC%2D159%2C%20an,inhibit%20angiogenesis%20in%20these%20tumours.